Clinical Trial Results:
An open-label study to assess the immune persistence in healthy Chinese toddlers primed in infancy with three doses of GSK Biologicals’ DTPa-IPV/Hib vaccine, and to assess the safety and immunogenicity of a booster dose of IPV and DTPa/Hib administered at 18 to 24 months of age.
Summary
|
|
EudraCT number |
2012-003324-20 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
16 Jan 2012
|
Results information
|
|
Results version number |
v1 |
This version publication date |
01 Apr 2016
|
First version publication date |
10 Jul 2015
|
Other versions |
v2 , v3 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
114386
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01449812 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
GlaxoSmithKline Biologicals
|
||
Sponsor organisation address |
Rue de l’Institut 89, Rixensart, Belgium, B-1330
|
||
Public contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2989904466, GSKClinicalSupportHD@gsk.com
|
||
Scientific contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2989904466, GSKClinicalSupportHD@gsk.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
16 Jan 2012
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
16 Jan 2012
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
16 Jan 2012
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
•To assess the persistence of antibodies to all vaccine antigens before the booster dose.
•To assess the immune response to the study vaccines in terms of seroprotection to diphtheria, tetanus, Haemophilus influenzae type b and poliovirus types 1, 2 and 3, and in terms of vaccine response to the pertussis antigens, one month after booster vaccination.
•To assess the immune response to the study vaccines in terms of antibody concentrations or titres for all antigens, one month after the booster dose.
|
||
Protection of trial subjects |
All subjects were supervised after vaccination/product administration with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
16 Oct 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
China: 825
|
||
Worldwide total number of subjects |
825
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
825
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||
Screening details |
During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms. | ||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||
Arm title
|
Infanrix+Hib/Poliorix 1 Group | ||||||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Infanrix+Hib™
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Subjects primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3, 4 months of age in the primary 112584 study, received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines at 18-24 months of age. The Poliorix™ and Infanrix+Hib™ vaccines were administered as an intramuscular (IM) injection into the upper sides of the left and right thighs, respectively.
|
||||||||||||||||||||||||||||
Investigational medicinal product name |
Poliorix™
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Subjects primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3, 4 months of age in the primary 112584 study, received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines at 18-24 months of age. The Poliorix™ and Infanrix+Hib™ vaccines were administered as an intramuscular (IM) injection into the upper sides of the left and right thighs, respectively.
|
||||||||||||||||||||||||||||
Arm title
|
Infanrix+Hib/Poliorix 2 Group | ||||||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Infanrix+Hib™
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Subjects primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4, 5 months of age in the primary 112584 study, received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines at 18-24 months of age. The Poliorix™ and Infanrix+Hib™ vaccines were administered as an intramuscular (IM) injection into the upper sides of the left and right thighs, respectively.
|
||||||||||||||||||||||||||||
Investigational medicinal product name |
Poliorix™
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Subjects primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4, 5 months of age in the primary 112584 study, received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines at 18-24 months of age. The Poliorix™ and Infanrix+Hib™ vaccines were administered as an intramuscular (IM) injection into the upper sides of the left and right thighs, respectively.
|
||||||||||||||||||||||||||||
Arm title
|
Control Group | ||||||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Infanrix+Hib™
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Subjects primed with 3 doses of the Infanrix+Hib™ vaccine at 2, 3, 4 months of age in the primary 112584 study, received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines at 18-24 months of age. The Poliorix™ and Infanrix+Hib™ vaccines were administered as an intramuscular (IM) injection into the upper sides of the left and right thighs, respectively.
|
||||||||||||||||||||||||||||
Investigational medicinal product name |
Poliorix™
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Subjects primed with 3 doses of the Infanrix+Hib™ vaccine at 2, 3, 4 months of age in the primary 112584 study, received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines at 18-24 months of age. The Poliorix™ and Infanrix+Hib™ vaccines were administered as an intramuscular (IM) injection into the upper sides of the left and right thighs, respectively.
|
||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Infanrix+Hib/Poliorix 1 Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Infanrix+Hib/Poliorix 2 Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Control Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Infanrix+Hib/Poliorix 1 Group
|
||
Reporting group description |
- | ||
Reporting group title |
Infanrix+Hib/Poliorix 2 Group
|
||
Reporting group description |
- | ||
Reporting group title |
Control Group
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Number of seropositive subjects for anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-diphtheria (anti-D). [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Before booster vaccination
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
|||||||||||||
|
|||||||||||||
Notes [2] - The record will be updated when the results become available. [3] - The record will be updated when the results become available. [4] - The record will be updated when the results become available. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of subjects with solicited local symptoms | ||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
During the 4-day (Days 0-3) post-vaccination period
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||
End point title |
Number of subjects with solicited general symptoms | ||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||
End point timeframe |
During the 4-day (Days 0-3) post-vaccination period
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Number of subjects with unsolicited AEs | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Within the 31-day (Days 0-30) period following booster vaccination
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Number of subjects with serious adverse events (SAEs). | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Throughout the entire study period
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Solicited local and general symptoms: during the 4-day (Days 0-3) post-vaccination period. AEs: within the 31-day (Days 0-30) period following booster vaccination. SAEs: throughout the entire study period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
14.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Infanrix+Hib/Poliorix 1 Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Infanrix+Hib/Poliorix 2 Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Control Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited local and general symptoms were only reported for subjects with a symptom sheet completed. [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited local and general symptoms were only reported for subjects with a symptom sheet completed. [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited local and general symptoms were only reported for subjects with a symptom sheet completed. [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited local and general symptoms were only reported for subjects with a symptom sheet completed. [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited local and general symptoms were only reported for subjects with a symptom sheet completed. [6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited local and general symptoms were only reported for subjects with a symptom sheet completed. [7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited local and general symptoms were only reported for subjects with a symptom sheet completed. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
12 Jul 2011 |
Due to significant revisions to the Chinese Pharmacopeia, the DTPa-IPV/Hib vaccine can currently not be locally retested and released in that country. The study design is therefore being modified to boost all subjects with the DTPa/Hib (Infanrix Hib) and IPV (Poliorix) vaccines. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |